Categories | News & Politics
Article
NCLA Condemns Federal Trade Commission’s Inclusion of Untrue Claims in Federal Court Complaint
February 21st, 2024
•
News & Politics
•
4 minute read
NCLA Condemns Federal Trade Commission’s Inclusion of Untrue Claims in Federal Court Complaint
Washington, DC – The Federal Trade Commission (FTC), in its initial filing before the U.S. District Court for the Northern District of California, has falsely accused Precision Patient Outcomes, Inc. (PPO) and CEO Margrett Lewis of unlawfully marketing and selling a dietary supplement called COVID Resist. The problem for FTC is PPO and Ms. Lewis never sold such a product—and FTC knows that. During six months or more of investigation, PPO provided FTC clear proof such sales never happened. So, there is simply no excuse for the agency to repeat this untrue claim, which undermines its entire groundless case. The New Civil Liberties Alliance will vigorously defend our clients PPO and Ms. Lewis and expose FTC’s deceit here in the process.Inspired by her personal experiences with health and wellness, Ms. Lewis became a tireless consumer and patient advocate. Drawing on a wide-cross section of information, she founded PPO, which develops precision medical solutions for wound care, scar management, and skin-renewing technologies. More recently, PPO began to develop and sell vitamin, mineral, and nutraceutical supplements. Prior to selling any supplements, PPO contacted FTC and asked it if there was any problem with the proposed product’s name and marketing. FTC would not say either way, so out of an abundance of caution and at great expense, PPO abandoned its trademarked name, removed and relabeled products, and changed its website and marketing. PPO never sold any “COVID Resist.”Despite PPO’s drastic changes, the fact that it sold no product under the COVID Resist label, and that PPO ceased selling any product called “VIRUS Resist” before FTC filed suit, FTC has continued to pursue an enforcement action against the company—and against Ms. Lewis individually—under the newly enacted Covid-19 Consumer Protection Act. FTC seeks to monitor Ms. Lewis’s and PPO’s activities for the next 20 years and obtain substantial penalties for selling fewer than 250 bottles of a supplement containing ingredients thousands of physicians across the country recommend to support immune health. FTC lacks the statutory and constitutional authority to pursue these penalties or this action.
Photo by Andrea Piacquadio on Unsplash
About Press Release
This post is an authorized copy of a press release and was not written by LegalReader.